Advances in studies of angiogenesis inhibitor

Abstract

Abstract: Angiogenesis is essential for cancer growth and metastasis, which is a crucial process as it furnishes tumor cell with enough nutrients and oxygen.Tumor size can be reduced and metastasis of tumor be blocked if the formation of new blood vessel networks is prevented.As the features of angiogenesis inhibitors are of low toxicity and have less acquired resistance, it comes to a new strategy to suppress tumor growth by restraining angiogenesis.

Key words: tumor, angiogenesis, MMPs, inhibitor

CLC Number:

R730.5

HUANG Wei, GUAN Yong-biao. Advances in studies of angiogenesis inhibitor[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(4): 376-380.

References

1 Hanahan D, Folkman J.Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis[J].Cell, 1996;86: 353-364.
2 Ferrara N,Gerber HP, LeCouter J.The biology of VEGF and its receptors[J].NatMed, 2003;9:669-676.
3 Muhammad WS.Anti-Angiogenesis Therapy in Pancreatic Carcinoma[J].JOP J Pancreas (Online), 2006;7:163-173.
4 Schueneman AJ, Himmelfarb E, GenG L, et al.SU11248 maintenance therapy prevents tumour regrowth after fractionated irradiation of murine tumour models[J].Cancer Res, 2003;63: 4009-4016.
5 Motzer RJ, Rini BI, Michaelson MD, et al.SU011248, a novel tyrosine kinase inhibitor, shows antitumour activity in secondline therapy for patients with metastatic renal cell carcinoma: results of a phase 2 trial[J].Proc Am Soc Clin Oncol, 2004; 23:381.
6 Morgan B, Thomas AL, Drevs J, et al.Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787 ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colourectal cancer and liver metastases: results from two phase I studies[J].J Clin Oncol, 2003;21: 3955-3964.
7 Steward WP, Thomas A, Morgan B, et al.Expanded phase I II study of PTK787 ZK 222584 (PTK ZK), a novel, oral angiogenesis inhibitor, in combination with FOLFOX-4 as first-line treatment for patients with metastatic colourectal[J].Proc Am Soc Clin Oncol, 2004;23:259.
8 George D, Michaelson, Oh WK, et al.Phase I study of PTK787 ZK 222584 (PTK ZK)in metastatic renal cell carcinoma[J]. Proc Am Soc Clin Oncol, 2003;22:385.
9 Willett CG, Boucher Y, Di Tomaso E, et al.Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer[J].Nat Med, 2004;10:145-147.
10 Posey JA, Ng TC, Yang B, et al.A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colourectal carcinoma[J].Clin Cancer Res, 2003;9:1323-1332.
11 Jimenoa J, Lopez-Martyna JA, Ruiz-Casadoa A, et al.Progress in the clinical development of new marine derived anticancer compounds[J].Anti-Cancer Drugs, 2004;15:321-329.
12 Dupont J, Camastra D, GordonMS, et al.Phase I study of VEGF TRAP in patients with solid tumours and lymphoma[J].Proc Am Soc Clin Oncol, 2003;22:194.
13 Pruthi RS, Derksen JE,Moore D.A pilot study of use of the cyclooxygenase-2 inhibitor celecoxib in recurrent prostate cancer after definitive radiation therapy or radical prostatectomy[J]. BJU Int, 2004;93:275-278.
14 Moore MJ, Hamm J, Dancey J, et al.Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas:a phase III trial of the National Cancer Institute of Canada Clinical Trials Group[J].J Clin Oncol, 2003;21:3296-3302.
15 Crombet T, Osorio M, Cruz T, et al.Use of the humanised antiepidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients[J].J Clin Oncol, 2004; 22:1646-1654.
16 RansonM.Epidermal growth factor receptor tyrosine kinase inhibitors[J].Br J Cancer, 2004;90:2250-2255.
17 Faivre SJ, Chieze S, Marty M, et al.Safety profile and pharmacokinetic analysis of MEDI-522, a novel humanised monoclonal antibody that targets avb3 integrin receptor, in patients with refractory solid tumours[J].Proc Am Soc Clin Oncol, 2003;22: 208.
18 FranksME, Macpherson GR, Figg WD.Thalidomide[J].Lancet, 2004;363:1802-1811.
19 Teo SK, Stirling DI, Zeldis JB.Thalidomide as a novel therapeutic agent:new uses for an old product[J].Drug Discovery Today, 2005;10:107-114.
20 Kulke M, Bergsland E, Ryan DP, et al.A phase II, open-label, safety, pharmacokinetic, and efficacy study of recombinant human endostatin in patients with advanced neuroendocrine tumours[J].Proc Am Soc Clin Oncol, 2003;22:239.
21 Gordon MS,Mendelson D, GuirguisMS, et al.ABT-510, an anti-angiogenic thrombospondin-1 (TSP-1)mimetic peptide, exhibits favorable safety profile and early signals of activity in a randomised phase IB trial[J].Proc Am Soc Clin Oncol, 2003; 22:195.
22 Dutcher JP.Mammalian Target of Rapamy cin Inhibition[J].Clin Cancer Res, 2004;10:6382S-6387S.
23 Vincent L, Kermani P, YounG LM, et al.Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling[J].J Clin Invest, 2005;115:2992-3006.
24 Cooney MM, Radivoyevitch T, Dowlati A, et al.Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose phase I study in patients with advanced cancer[J].Clin Cancer Res, 2004;10:96-100

[1]	HAO Xiao, ZHAO Mei, WANG Wenjing, ZHANG Feifei, LIU Huiliang, DANG Yi, LI Shuren, QI Xiaoyong. Application of sodium-glucose cotransporter 2 inhibitors in acute myocardial infarction [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 824-831.
[2]	FU Ting, LI Fang, PAN Dayan, XIA Yuanyuan, ZHANG Qiuyuan. miR-718 from exosomes of lung cancer cells induces angiogenesis by targeting PTEN [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 624-632.
[3]	WANG Juan, LIU Weiying, YE Yucai, FU Wenli, ZHANG Sha, LI Leping. Research progress of norepinephrine reuptake inhibitor combined with antimuscarinic in the treatment of obstructive sleep apnea [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 714-720.
[4]	LI Yanyang, WANG Yunjiao, LV Shichao. Effects and mechanism of traditional Chinese medicine injection in prevention and treatment of cardiotoxicity induced by antineoplastic drugs [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 572-577.
[5]	LI Ruoning, GUO Zhanli, WANG Yuan, SUN Jianjun. Platelet-endothelial aggregation receptor 1 and its mediated signalling pathway Advances in the study of the role of platelets and endothelial cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 438-444.
[6]	WANG Siyu, LI Jiawei, LI Chenghao, LI Ling, GUO Qingyang, QIU Lu, ZHOU Shiqin, LIU Yongqi. Research progress of lactate dehydrogenase A in digestive system tumors and related drugs [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 445-454.
[7]	SHEN Jiaqing, LIU Yi. Mechanism of tyrosine kinase 2 inhibitors in treatment of plaque psoriasis and their progress in clinical trials [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 323-330.
[8]	LI Shan, LIU Yixin, REN Feifei, LI Xiangchen, ZHANG Zhiqing. Research progress of natural plant active ingredients in reversing tumor multidrug resistance by down-regulating P-gp [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 331-340.
[9]	LIU Nanyu, YUE Hongmei, SONG Peipei, WEI Jifang, WEI Yaqian, XIE Yingying, WANG Jiaqi . PDE4 inhibitors serve as therapeutic targets for pulmonary fibrosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 355-360.
[10]	WANG Dan, YAN Xiaoli, ZHANG Yuan. Helicobacter pylori infection influences the efficacy of immunotherapies for gastric cancer#br# [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 228-234.
[11]	ZHANG Wei, WANG Hongyuan, LEI Xiaohang, ZHAO Yingshuai, LV Weichao, ZHANG Jianguo. BCG + piroxicam versus BCG + gemcitabine for prevention of postoperative recurrence in intermediate- and high-risk bladder cancer and effects on serum AGR and PON1 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1146-1153.
[12]	LIU Dan, LIU Ming, JIN Liangyou, PAN Juan, XIN Haoru, LIU Mengyuan, LI Xin, ZHENG Kun, FENG Xiaoling. Research progress on the antitumor activity of costunolide [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1168-1176.
[13]	LIU Jiajun, QUE Zujun, TIAN Jianhui. Comparative study on the ability of active ingredients in Jinfukang to decrease neutrophils recruiting by lung cancer circulating tumor cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 1-9.
[14]	HUANG Hao, JIA Hong, WANG Xiaoshuang, ZHANG Lu, JIANG Hua. Effects of co-culture of dendritic cells loaded with MAGE-A3 antigen and cytokine-induced killer cells on tumor stem cells and malignant progression of endometrial cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 42-50.
[15]	HUANG Xiaoming, DU Ye, LIN Shaoming, SHEN Guanle. Exploratory study of the influence of respiratory microbiology on the efficacy of PD-1 inhibitors monotherapy for patients with advanced non-small cell lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 66-74.